2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
189
Neoplasm Metastasis
24
Neoplasms
23
Ovarian Neoplasms
12
Sarcoma
10
Pancreatic Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Melanoma
7
Endometrial Neoplasms
7
Colorectal Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Prostatic Neoplasms
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Multiple Myeloma
6
Lymphoma, Non-Hodgkin
6
Head and Neck Neoplasms
6
Carcinoma, Renal Cell
6
Breast Diseases
6
Recurrence
5
Medulloblastoma
5
Lung Neoplasms
5
Leukemia, Myeloid, Acute
5
Triple Negative Breast Neoplasms
4
Sarcoma, Ewing
4
Neoplasms by Site
4
Lymphoma, Mantle-Cell
4
Liposarcoma
4
Glioma
4
Glioblastoma
4
Colonic Neoplasms
4
Interventions
Tamoxifen
4
Exercise
3
pyrotinib
2
abemaciclib
2
Paclitaxel
2
Metformin
2
Letrozole
2
Cyclophosphamide
2
Control Groups
2
Capecitabine
2
Bupivacaine
2
Aromatase Inhibitors
2
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
palbociclib
1
iniparib
1
exemestane
1
durvalumab
1
darolutamide
1
Yoga
1
Waiting Lists
1
Vitamin D
1
Tumor Burden
1
Tretinoin
1
Trastuzumab
1
Tocopherols
1
Thioctic Acid
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Cancer Female
×
palbociclib
×
Clear all
NCT03065621
2023-04-19
NeoRHEA
Jules Bordet Institute
Phase 2
Completed
100 enrolled